Inhibitor of inflammasome activation
AssigneeKracie Holdings, Ltd.
InventorsShimpei Watanabe, Ayako Arai, Yuichi Takajo, Satoshi Inamasu, Satoshi Yomoda, Akiko Ohno, Yuko Kitahara, Taisaku Kanatani
Life of this patent
Estimating the term…
Abstract
To provide a novel inflammasome inhibitor capable of inhibiting activation of inflammasome, the present inventors newly found that arctigenin reduces the amount of 1L-1β released and the amount of activated caspase-1 upon stimulation with ATP, palmitic acid, MSU and Poly(dA:dT) and thus has an effect of inhibiting inflammasome activation. The present invention provides an inhibitor of inflammasome activation that comprises arctigenin as an active ingredient.
Claims2
A method for treating or improving non-alcoholic steatohepatitis (NASH) through inhibition of inflammasome activation including administering arctigenin and/or arctiin to a subject in need thereof, wherein arctigenin and/or arctiin inhibits release of inflammatory cytokines as IL-1αa, IL-1β, IL-6, IL-18, IL-33, TNF-α, and HMGB1 in the subject after administration.
Dependencies are inferred from the claim text.